Spots Global Cancer Trial Database for A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Official Title: A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT00544960
Conditions
Study Description
Brief Summary: This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer
Detailed Description: Further Study Details provided by Ascenta.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Durham, North Carolina, United States
Research Site, Arkhangelsk, , Russian Federation
Research Site, Chelyabinsk, , Russian Federation
Research Site, Ekaterinburg, , Russian Federation
Research Site, Kaliningrad, , Russian Federation
Research Site, Kazan, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Sites (4), Saint Petersburg, , Russian Federation
Research Site, Samara, , Russian Federation
Research Site, Stavropol, , Russian Federation
Research Site, Voronezh, , Russian Federation
Research Site, Dnipropetrovsk, , Ukraine
Research Site, Donetsk, , Ukraine
Research Site, Kharkiv, , Ukraine
Research Site, Kyiv, , Ukraine
Research Site, Lugansk, , Ukraine
Research Site, Uzhgorod, , Ukraine
Research Site, Zaporizhzhya, , Ukraine
Contact Details
Name: Lance Leopold, MD
Affiliation: Ascenta Therapeutics, Inc.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
